Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 23, n. 1, 2022. DOI: 10.7175/fe.v23i1.1539. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1539. Acesso em: 28 dec. 2025.